| Actelion - A global biopharmaceutical leader | ||
| Actelion | Actelion Ltd Actelion Pharmaceuticals Ltd | |
| Corporate structure | Actelion Ltd is a public company and listed on the Swiss stock exchange (SIX) | |
| Incorporated | 17 December 1997 | |
| Founding team | Jean-Paul Clozel, Walter Fischli, Thomas Widmann, Martine Clozel, Andre Mueller | |
| Head office | Actelion Ltd & Actelion Pharmaceuticals Ltd Gewerbestrasse 16 4123 Allschwil, Switzerland phone + 41 61 565 65 65 fax + 41 61 565 65 00 | |
| Global presence | Actelion has subsidiaries with marketing and sales in more than 25 countries, covering all key pharmaceutical markets worldwide. | |
| Products | Tracleer® (bosentan) is an oral dual endothelin receptor antagonist, which is currently licensed for the treatment of pulmonary arterial hypertension (WHO Group I), a chronic, life-threatening disorder which severely compromises the function of the lungs and heart. In the United States, Tracleer® is approved for the treatment of pulmonary arterial hypertension functional class II - IV to improve exercise capacity and decrease the rate of clinical worsening. Patients with class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of liver injury in class II patients, which may preclude future use as their disease progresses. In Europe it is approved for treatment of PAH functional class III to improve exercise capacity and symptoms, as well as PAH functional class II, where some improvements have also been shown. In the EU Tracleer® is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease. Regulatory review and approval for the inclusion of functional class II in the Tracleer® label is ongoing on a worldwide basis. Ventavis® (iloprost) is an inhaled formulation of iloprost, approved for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms. Epoprostenol for Injection is a prostanoid vasodilator, indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy. Zavesca® (miglustat) is the first and only oral medication approved for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease, and it may only be used in those patients for whom enzyme replacement therapy is unsuitable. Zavesca® is also approved in the European Union for the treatment of progressive neurological manifestations in adult patients and pediatric patients with Niemann-Pick type C disease (NP-C). Zavesca® is the first treatment to be approved for patients with Niemann-Pick type C disease, a very rare, invariably progressive and eventually fatal neurodegenerative genetic disorder affecting both children and adults. | |
